# Gameto

> Gameto is a clinical-stage biotechnology company developing reproductive-health products from engineered ovarian cells. Its lead program, Fertilo, supports egg maturation outside the body for IVF and egg freezing after reduced hormonal stimulation. It is available through selected international clinics and remains investigational in the United States; Deovo and Ameno extend the platform into ovarian research and menopause development.

- **Founded:** 2020
- **Headquarters:** New York, United States
- **Founders:** Dina Turner (Co-founder and Chief Executive Officer; formerly Dina Radenkovic), Martin Varsavsky (Co-founder and Chairman)
- **Products:** Fertilo, Deovo, Ameno, Clinic onboarding and embryologist training
- **Notable:** 2023 Human Reproduction study assessed eggs from 67 participants and reported improved maturation and euploid embryo formation versus conventional IVM media., First reported Fertilo live birth: a baby girl born December 7, 2024, in Lima, Peru; announced December 16., FDA IND clearance for Phase 3 investigation announced January 2025; this is not U.S. marketing approval.

## Products & services

- **Fertilo** — iPSC-derived ovarian support cells used in laboratory co-culture to mature retrieved immature eggs for IVF and egg freezing with reduced stimulation. Investigational in the United States; in Phase 3.
- **Deovo** — Development-stage ovarian organoid platform for disease modeling, drug discovery, and safety testing.
- **Ameno** — Preclinical cell-based program intended to restore responsive ovarian hormone production and address unwanted effects of menopause; supported by an ARPA-H award.
- **Clinic onboarding and embryologist training** — Protocols, training resources, and ongoing support to integrate Fertilo into fertility laboratories, including a 32-lesson online course.

## Achievements

- 2023 Human Reproduction study assessed eggs from 67 participants and reported improved maturation and euploid embryo formation versus conventional IVM media.
- First reported Fertilo live birth: a baby girl born December 7, 2024, in Lima, Peru; announced December 16.
- FDA IND clearance for Phase 3 investigation announced January 2025; this is not U.S. marketing approval.
- Fertilo manufacturing and clinical translation study published in Cell Stem Cell in February 2026.
- $117 million in disclosed venture funding plus a separate $10 million ARPA-H award.

## Latest updates

- **2026-09** — FIRST registry update posted September 29 lists recruiting, estimated enrollment of 500, estimated primary completion May 2027, and study completion January 2028.
- **2026-02** — Clinical-grade ovarian support cell manufacturing and IVF translation paper published in Cell Stem Cell, February 5.
- **2026-01** — Additional Harvard intellectual property for inducing early meiosis exclusively licensed to expand the ovarian organoid platform.
- **2025-08** — $44 million Series C announced August 12 to support Fertilo Phase 3 and reproductive-health development.

## Links

- Website: https://www.gametogen.com/
- LinkedIn: https://www.linkedin.com/company/gameto-inc/
- Twitter/X: https://twitter.com/gametogen
- Instagram: https://www.instagram.com/gametogen/

---

Profile page: https://yespress.io/gameto
Published by YesPress — https://yespress.io
Last updated: 2026-10-04